2023-04-25 09:15:55 ET
- NanoViricides ( NYSE: NNVC ) said it is exploring other antiviral applications for the active pharmaceutical ingredient in NV-387, its COVID-19 candidate.
- The company said that NV-387 has demonstrated broad spectrum activity against seasonal coronaviruses and SARS-CoV-2 in pre-clinical studies. As a result, the candidate could have broad spectrum activity against other viral infections.
- NanoViricides ( NNVC ) is already investigating , in the pre-clinical stage, NV-387 for poxvirus family and respiratory syncytial virus (RSV). The company plans to expend to other viruses that cause lung infections, such as parainfluenza viruses and human metapneumovirus.
- Shares are down ~5% in premarket trading.
For further details see:
NanoViricides looking at other uses for COVID drug candidate NV-387